Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Preferred Shares (2016 - 2021)

Vistagen Therapeutics (VTGN) has disclosed Preferred Shares for 9 consecutive years, with $2300.0 as the latest value for Q2 2021.

  • Quarterly Preferred Shares rose 91.67% to $2300.0 in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $2300.0 through Jun 2021, up 91.67% year-over-year, with the annual reading at $2300.0 for FY2021, 0.0% changed from the prior year.
  • Preferred Shares hit $2300.0 in Q2 2021 for Vistagen Therapeutics, roughly flat from $2300.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $2300.0 in Q2 2017 to a low of $500.0 in Q1 2017.
  • Historically, Preferred Shares has averaged $1552.9 across 5 years, with a median of $1200.0 in 2018.
  • Biggest five-year swings in Preferred Shares: plummeted 86.49% in 2017 and later skyrocketed 360.0% in 2020.
  • Year by year, Preferred Shares stood at $2300.0 in 2017, then changed by 0.0% to $2300.0 in 2018, then tumbled by 78.26% to $500.0 in 2019, then surged by 360.0% to $2300.0 in 2020, then changed by 0.0% to $2300.0 in 2021.
  • Business Quant data shows Preferred Shares for VTGN at $2300.0 in Q2 2021, $2300.0 in Q1 2021, and $2300.0 in Q4 2020.